Atai Life Sciences Poised for Success With Rigorous Clinical Trials | NASDAQ:ATAI, ETR:9VC
Don't Freak Out. It Isn't the End of the Line for Psychedelic Medicines. -- Barrons.com
By Josh Nathan-Kazis Turn on, tune in, drop in value. A frigid reception for one novel psychedelic treatment by a Food and Drug Administration advisory committee doesn't spell doom for all psychedel
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment
A panel of advisors to the Food and Drug Administration (FDA) rejected MDMA as a treatment for post-traumatic stress disorder (PTSD) on Tuesday, citing a lack of evidence that the benefits would outwe
What's Going On With MindMed And Psychedelic Stocks?
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) shares are trading lower Wednesday after a Food and Drug Administration (FDA) panel rejected the approval of MDMA therapy for people with post-traumatic stre
FDA advisory group refuses MDMA marketing authorization; psychedelic concept stocks slump.
The independent advisory group of the US FDA voted against the marketing authorization application for the psychiatric drug MDMA, causing a pre-market drop for the hallucinogenic drug developer.
Psychedelic Stocks Fall as FDA Panel Rejects MDMA Therapy
FDA Advisory Panel Fails to Endorse Psychedelic MDMA Therapy for PTSD
Psychedelic Stocks Mixed as FDA Comments on MDMA Therapy
Atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference
NEW YORK and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders,
ATAI Life Sciences Announces Appointment of Scott Braunstein and Laurent Fischer as Independent Directors >ATAI
ATAI Life Sciences Announces Appointment of Scott Braunstein and Laurent Fischer as Independent Directors >ATAI
Press Release: Atai Life Sciences Strengthens Board With Appointment of Two New Independent Directors
atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) ("atai" or "Company"), a
Atai Life Sciences Bolsters Board With Two New Directors | NASDAQ:ATAI, ETR:9VC
ATAI Life Sciences(ATAI.US) Officer Sells US$290.5K in Common Stock
$ATAI Life Sciences(ATAI.US)$ Officer Brand Florian sold 151.3K shares of common stock on May 16, 2024 at an average price of $1.92 for a total value of $290.5K.Source: Announcement What is statement
Atai Life Sciences Insider Sold Shares Worth $290,502, According to a Recent SEC Filing
Florian Brand, Co-Founder & Chief Executive Officer, on May 16, 2024, sold 151,303 shares in Atai Life Sciences (ATAI) for $290,502. Following the Form 4 filing with the SEC, Brand has control over a
Express News | HC Wainwright & Co. Reiterates Buy on ATAI Life Sciences, Maintains $15 Price Target
ATAI Life Sciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/17/2024 702.14% HC Wainwright & Co. → $15 Reiterates Buy → Buy 04/04/2024 — Cantor Fitzgerald Reiterat
Buy Rating Affirmed for ATAI Life Sciences Amid Promising TRD Treatment Developments and Strategic Growth Potential
Buy Recommendation for ATAI Life Sciences Amidst Cost-Optimization and Promising Clinical Milestones
Atai Life Sciences Poised to Create Value as Psychedelic Therapies Gain Traction, Analysts Believe | NASDAQ:ATAI, ETR:9VC
Analysts Offer Insights on Healthcare Companies: Athira Pharma (ATHA), Celcuity (CELC) and ATAI Life Sciences (ATAI)
No Data